Indications |
Intravenous Susceptible infections Adult: Combined with cilastatin: (as anhydrous imipenem) 1-2 g daily in divided doses every 6-8 hr, given via IV infusion. Doses 250 or 500 mg are infused over 20-30 min, and doses of 750 mg or 1 g over 40-60 min. Max: 4 g/day or 50 mg/kg. Child: >40 kg: same as adult dose. Child >3 mth and <40 kg: 15-25 mg/kg every 6 hr by IV infusion. Doses up to 90 mg/kg may be given to older children with cystic fibrosis. Neonates and infants <3 mth: 4 wk-3 mth, 25 mg/kg every 6 hr; 1-4 wk, 25 mg/kg every 8 hr; up to 1 wk, 25 mg/kg every 12 hr. Max: >40 kg: 4 g/day or 50 mg/kg; <40 kg: 2 g/day. Renal impairment: Max doses based on CrCl.
Intravenous Prophylaxis of surgical infections Adult: 1 g may be given on induction of anaesthesia, followed by 1 g 3 hr later, with additional doses of 500 mg at 8 and 16 hr after induction if necessary. Intramuscular Mild to moderate susceptible infections Adult: 500 or 750 mg every 12 hr. Intramuscular Uncomplicated gonorrhoea Adult: 500 mg as a single dose. Special Populations: Max IV doses in renal impairment: CrCl 31-70 ml/min: 500 mg every 6-8 hr CrCl 21 to 30 ml/min: 500 mg every 8-12 hr CrCl 6-20 ml/min: 250 mg (or 3.5 mg/kg, whichever is the lower) every 12 hr or occasionally 500 mg every 12 hr. CrCl ≤5 ml/min: should only be given imipenem if haemodialysis is started within 48 hr. Imipenem and cilastatin are cleared from the body by haemodialysis and doses should be given after a dialysis session and then every 12 hr. |
||||||||||
Contraindications |
Hypersensitivity. | ||||||||||
Warnings / Precautions |
Caution when used in patients with known hypersensitivity to other β-lactams due to possibility of cross-sensitivity. CNS disorders such as epilepsy; renal, hepatic impairment; pregnancy, lactation. | ||||||||||
Adverse Reactions |
Skin rashes, urticaria, eosinophilia, fever, nausea, vomiting, diarrhoea, tooth or tongue discoloration, and altered taste. Erythema multiforme, exfoliative dermatitis. Pain and thrombophlebitis may occur at the inj site. Potentially Fatal: Severe anaphylactic reactions. Stevens-Johnson syndrome and toxic epidermal necrolysis. |
||||||||||
Drug Interactions |
Increased risk of seizures when used with ganciclovir. Ciclosporin may increase neurotoxicity of ifosfamide; ifosfamide may also raise serum levels of ciclosporin. Serum levels may be increased by uricosuric agents. May reduce efficacy of valproic acid; monitor. See Below for More imipenem Drug Interactions |
||||||||||
Mechanism of Actions |
Imipenem is bactericidal and acts by inhibiting bacterial cell wall synthesis. It has a very broad spectrum of activity in vitro, including activity against Gram-positive and Gram-negative aerobic and anaerobic organisms, and is stable to hydrolysis by β-lactamases. Distribution: Widely distributed in body tissues and fluids. Metabolism: Partially hydrolised in the kidneys. Excretion: In the urine via glomerular filtration and tubular secretion. |
||||||||||
Storage Conditions |
Intramuscular: Dry powder: Store below 25°C. When reconstituted, satisfactory potency is maintained for 4 hr at room temperature and for 24 hr under refrigeration (5°C). Solutions should not to be frozen. Intravenous: Dry powder: Store below 25°C. When reconstituted, satisfactory potency is maintained for 4 hr at room temperature and for 24 hr under refrigeration (5°C). Solutions should not to be frozen. | ||||||||||
Storage |
Intramuscular: Dry powder: Store below 25°C. When reconstituted, satisfactory potency is maintained for 4 hr at room temperature and for 24 hr under refrigeration (5°C). Solutions should not to be frozen. Intravenous: Dry powder: Store below 25°C. When reconstituted, satisfactory potency is maintained for 4 hr at room temperature and for 24 hr under refrigeration (5°C). Solutions should not to be frozen. | ||||||||||
Available As |
|
Imipenem
Post Review about Imipenem Click here to cancel reply.
Imipenem Containing Brands
Imipenem is used in following diseases
Drug - Drug Interactions of Imipenem
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.